Teleflex Incorporated (TFX) reported quarterly earnings results on Thursday, Jul-28-2016. The company said it had a profit of $1.89 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.15. Analysts had a consensus of $1.74. The company posted revenue of $473.60 million in the period, compared to analysts expectations of $468.18 million. The company’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.42 EPS.
Many Wall Street Analysts have commented on Teleflex Incorporated. Teleflex Incorporated was Downgraded by KeyBanc Capital Mkts to ” Sector Weight” on Jul 12, 2016. Company shares were Reiterated by Barclays on Jun 14, 2016 to “Overweight”, Firm has raised the Price Target to $ 183 from a previous price target of $170 .
Teleflex Incorporated opened for trading at $179.83 and hit $181.53 on the upside on Thursday, eventually ending the session at $180.57, with a gain of 3.34% or 5.83 points. The heightened volatility saw the trading volume jump to 4,54,686 shares. Company has a market cap of $7,872 M.
In a different news, on Jun 7, 2016, Stuart A Randle (director) sold 797 shares at $166.10 per share price. According to the SEC, on May 18, 2016, Thomas Anthony Kennedy (Senior VP, Global Operations) sold 15,102 shares at $160.20 per share price. On Aug 21, 2015, Patricia C Barron (director) sold 1,500 shares at $132.74 per share price, according to the Form-4 filing with the securities and exchange commission.
Teleflex Incorporated is a provider of medical technology products. The Company designs develops manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company also markets and sells its products to hospitals and healthcare providers. The Company operates its business in six segments: Vascular North America; Anesthesia/Respiratory North America; Surgical North America; Europe the Middle East and Africa (EMEA); Asia and Original Equipment Manufacturer (OEM). The Company manufactures its products at 26 manufacturing sites with manufacturing operations located in the Czech Republic Germany Malaysia Mexico and the United States. The Companys specialty product line consists of a range of catheters including Foley intermittent external and suprapubic; urine collectors; catheterization accessories and products for operative endourology.